Table 9.
Published clinical TCR-T therapy for solid tumors.
| Target | Disease | Vector | Pretreatment | Dose | No. of patients | Phage | Response | Country | References |
|---|---|---|---|---|---|---|---|---|---|
| MART-1 | Metastatic melanoma | Retrovirus | Chemotherapy | 1.5 × 109−1.07 × 1011 /person | 20 | II | 30% objective antitumor response | United States | (107) |
| Gp100 | Metastatic melanoma | Retrovirus | Chemotherapy | 1.8 × 109−1.1 × 1011 /person | 16 | II | 19% objective antitumor response | United States | (107) |
| CEA | Metastatic colorectal | Retrovirus | Chemotherapy | 2–4 × 108/person | 3 | – | Grade 2/3 diarrhea | United States | (108) |
| NY-ESO-1 | Metastatic melanoma/synovial cell sarcoma | Retrovirus | Chemotherapy | 1.6 × 1010−1.3 × 1011/person | 17 | I | 2 complete remission; 1 partial remission | United States | (109) |
| NY-ESO-1 | Multiple myeloma | Lentivirus | Chemotherapy | Average dose of 2.4 × 109/person | 20 | I/II | 80% remission; | United States | (104) |
| MAGE-A3 | Metastatic melanoma/multiple myeloma | Lentivirus | CY | 2.4–5.3 × 109/person | 2 | III/IV | 2 died for cardiac toxicity | United States | (110) |
| MAGE-A4 | Esophageal cancer | Retrovirus | Surgery; radiotherapy; chemotherapy | 2 × 108−5 × 109/person | 10 | I | 7/10 tumor progression | Japan | (111) |